Elsevier,
Journal of Vascular Surgery, Volume 81, June 2025
This study indicates neurofibrillary tangles(NFT) level detection in patients with extracranial carotid atherosclerotic disease (ECAD) could enable earlier identification of those at high risk for developing Alzheimer's and other dementias, sometimes decades before symptoms. As blood-based assays to quantify NFT's are more clinically available, this could guide more targeted prevention and early treatment strategies for patients.
Elsevier,
Pharmacological Research, Volume 216, June 2025
The article discusses the potential of glucagon-like peptide-1 (GLP-1) receptor agonists (GRA) as novel therapeutic agents for neurodegenerative diseases (NDs) like Alzheimer's disease (AD) and Parkinson's disease (PD). GRA have shown promising effects in modulating neuroinflammation, oxidative stress, mitochondrial and autophagic functions, and protein misfolding in preclinical studies. Clinical trials have demonstrated that GRA like exenatide, liraglutide, and lixisenatide can improve motor deficits in PD and cognitive function in AD patients.
Elsevier,
IBRO Neuroscience Reports, Volume 18, June 2025
This study investigated the prevalence and impact of auditory agnosia for environmental sounds in individuals with Alzheimer’s disease (AD), finding that over half exhibited signs of this central auditory dysfunction along with a high rate of unrecognized peripheral hearing loss. Although these factors appeared independent and showed limited direct effect on measured quality of life, possibly due to sheltered living environments and lack of patient awareness, they jointly contribute to daily functional decline, highlighting the importance of early hearing assessment and intervention in AD management.
Elsevier,
Journal of Prevention of Alzheimer's Disease, Volume 12, 1 June 2025
The article discusses the need for and challenges of developing combination therapies for Alzheimer's disease, given the complex and multifactorial nature of the disease. As of 2024, there were 21 combination trials in the pipeline, primarily involving repurposed agents targeting processes like inflammation, senescence, and amyloid-tau interactions. Key challenges include distinguishing individual drug effects and managing the operational complexity of combination trials.f
Elsevier,
Journal of Prevention of Alzheimer's Disease, Volume 12, 1 June 2025
This article provides a narrative review of the relationships between modifiable lifestyle factors and plasma biomarkers of Alzheimer's disease (AD). The key findings are that better nutrition, more physical activity, and good sleep quality are associated with more favorable plasma AD biomarker profiles, potentially reflecting less cerebral AD pathology.
Elsevier,
Acta Pharmaceutica Sinica B, Volume 15, June 2025
The article discusses the critical role of the mitochondrial contact site and cristae organizing system (MICOS) complex in the pathogenesis of Alzheimer's disease (AD). It highlights how MICOS abnormalities, including subunit dysfunction and interactions with disease-associated proteins, to hallmark AD pathologies such as amyloid-β accumulation, neurofibrillary tangle formation, and neuronal apoptosis. The article suggests that targeting MICOS subunits with pharmacological interventions may provide novel therapeutic insights for AD treatment.
